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This pilot phase I/II study intended to determine the maximum tolerated dose of cyclophosphamide and thiotepa administered
on four consecutive courses with peripheral blood progenitor cell and granulocyte-colony stimulating factor support, as ﬁrst-
line therapy for hormone-refractory metastatic breast cancer patients. Twenty-eight patients were entered in the study. After
two courses of epirubicin (120 mg m
72) and cyclophosphamide (2 g m
72) followed by granulocyte-colony stimulating factor
injection and leukaphereses, patients received four cycles of cyclophosphamide and thiotepa. Each cycle was followed by
peripheral blood progenitor cell and granulocyte-colony stimulating factor supports, then repeated every 28 to 35 days. Six
escalating dose levels of cyclophosphamide and thiotepa were planned, beginning at cyclophosphamide 1.5 g m
72 and
thiotepa 200 mg m
72. At least three patients were enrolled for each dose level. Eighteen patients completed the study. The
maximum tolerated dose was 3000 mg m
72 cyclophosphamide and 400 mg m
72 thiotepa per course. Haematological
toxicity was manageable on an outpatient basis and did not increase signiﬁcantly with dose escalation. Dose-limiting toxicity
was chemotherapy-induced immuno-suppression, which resulted in one toxic death and two life-threatening infections. Median
times to treatment failure and survival were 11 and 26 months, respectively. Three patients were alive, free of disease 30
months after completion of the study. Such therapy allows for high-dose intensity and high cumulative doses on a short period
of time with manageable toxicity.
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The clinical course of metastatic breast cancer is variable, depend-
ing on individual responsiveness to treatment. Women with
metastatic breast cancer are generally considered as incurable, with
a median survival of about 2 years after documentation of metas-
tases (Honig, 1996). Conventional chemotherapy regimens produce
40 to 80% objective response rates with median time to progres-
sion of less than 1 year (Clavel and Catimel, 1993; Nabholtz et
al, 2001). Until now, high-dose chemotherapy (HDCT) regimens
with autologous bone marrow or peripheral blood progenitor cell
(PBPC) reinfusion have yielded high response rates, but demon-
strated no survival improvement, in particular no obvious
increase in the rate of long term survivors in currently available
phase III trials (Stadtmauer et al, 2000; Antman, 2001). Hryniuk
and Bush (1984) have suggested that chemotherapy regimens
should be designed to maximise dose intensity rather than peak
dose. This approach is further supported by the hypothesis of
gompertzian growth of tumour cells in-vivo, which implies that
multiple cycles of HDCT might be more effective than a single
intensiﬁcation course (Norton, 1988).
We planned the ERASM2A protocol as a phase I/II trial with the
aim of developing an effective strategy allowing quadruple intensi-
ﬁcation with cyclophosphamide (CPA) and thiotepa (TTP) on an
outpatient basis. These particular alkylating agents were chosen
because (i) they are both highly potent against breast cancer, (ii)
they lack major extra-haematological toxicity and (iii) they exhibit
steep dose-response curves (Teicher et al, 1988; Eder et al, 1988).
PATIENTS AND METHODS
Patients
Patients who entered the study were required to have histologically
proven metastatic adenocarcinoma of the breast with disease that
was measurable or assessable (i.e. disease localisation not bi-dimen-
sionally measurable but that could be monitored for complete
response to treatment or progression). Patients should not have
received chemotherapy for metastatic disease and their disease
had to be hormone-refractory, i.e. receptor-negative for both
oestrogen and progesterone, or progressive after hormonal therapy.
Other requirements included: (1) age 561 years; (2) Eastern
Cooperative Oncology Group (ECOG) performance status 0 or 1;
(3) no adjuvant chemotherapy within 3 months of the diagnosis
of metastatic disease; (4) normal left ventricular ejection fraction;
(5) normal hepatic, renal and haematopoietic functions; (6) no
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www.bjcancer.combrain metastasis; (7) no previous irradiation to the pelvis; and (8)
no history of other malignancy. The protocol was approved by the
Comite ￿ Consultatif de Protection des Personnes soumises a ` la
Recherche Biome ￿dicale of Lyon. Informed consent was obtained
from all patients prior to entry in the study.
Treatment plan
The study design is depicted in Figure 1. The treatment schedule is
enumerated from the ﬁrst day of the ﬁrst chemotherapy cycle. The
ﬁrst two cycles of chemotherapy consisted of epirubicin (EPI)
120 mg m
72 and CPA 2 g m
72 (EC regimen) given over 1 h at
day 1 and day 15. G-CSF (ﬁlgrastim, 5 mg kg day
71) was adminis-
tered daily by subcutaneous injection from day 5 to day 14, then
from day 19 to day 28. Leukaphereses were performed on days
13, 14, 27 and 28. If necessary, subsequent leukaphereses were
performed on days 29 and 30. A minimum of 10610
6 CD34+ cell
kg
71 had to be harvested. This was the quantity required for ﬁve
reinjections (four planned and one back-up). No treatment delays
were allowed for the second EC regimen. When neutrophil count
was below 1610
9 l
71 and/or platelet count was below
75610
9 l
71 at day 14, the second EC was administered with
90 mg m
72 EPI and 1.5 g m
72 CPA.
Four courses of high-dose CPA and TTP (CPA/TTP regimen)
with G-CSF and PBMC support were administered every 4 to 5
weeks, starting at day 35. CPA and TTP were administered as a
48-h continuous infusion on days 35 and 36. Semi-saline hyperhy-
dration (3 l m
2 d
71) and mesna 1 g m
2 day
71 was started at day
35, then carried on to day 37. PBPC (2610
6 CD34+ kg
71) were
reinfused on day 39 and G-CSF (5 mg kg day
71) was started on
day 40, then continued until the patient achieved a sustained
neutrophil count over 0.5610
9 l
71 for 3 days. Patients were
discharged from the hospital at day 39, then readmitted in case
of febrile neutropenia or other severe toxicity. The four CPA/
TTP cycles were repeated every 28 to 35 days. No treatment delays
were allowed. If neutrophil count was below 0.5610
9 l
71 and/or
platelet count was below 50610
9 l
71 at a maximum of 35 days
from previous cycle, the patient was withdrawn from the study
for haematological toxicity.
Dose escalation
The starting doses of CPA and TTP were 1.5 g m
72 and
200 mg m
72, respectively. Six escalating dose levels were planned
(Table 1). Doses were assigned at registration and no dose-escala-
tion was allowed in individual patients. Three patients were treated
at each dose level. Before escalating to the next dose level, all three
patients had to have completed the full treatment and then been
observed for acute toxicity for at least 2 weeks. If any of the three
patients developed a dose-limiting toxicity (DLT), one more
patient was to be entered at the same dose level. If a second patient
developed DLT, a ﬁfth patient was to be entered at the same dose
level. Finally, if a third patient at a given dose developed DLT, this
dose level was deﬁned as the maximum tolerated dose (MTD).
Deﬁnition of dose-limiting toxicity
Toxicity was graded according to the National Cancer Institute
Common Toxicity Criteria (NCI-CTC). DLT was deﬁned as
follows: Neutrophil count below 0.5610
9 l
71 and/or platelet count
below 50610
9 l
71 at the theoretical starting day of a new CPA/
TTP cycle (max. 35 days from previous cycle), or any grade 3 or
4 life-threatening non-haematological toxicity.
Patients and treatment evaluation
Pre-study evaluation included medical history and physical exami-
nation, tumour measurement, CT-scans of head, chest and
abdomen, bone scan, left ventricular ejection fraction, complete
blood count, serum biochemistry plus liver function tests, tumour
markers, bone marrow aspiration and biopsy.
Patients were monitored for toxicity at least weekly throughout
treatment. Complete blood count was performed three times a
week and serum biochemistry plus liver function tests twice a week.
Assessment of tumour response was performed at the time of the
ﬁrst CPA/TTP cycle, then repeated 8 weeks after the fourth CPA/
TTP cycle in the absence of clinical or biological evidence of early
progression. Tumour response was assessed according to the WHO
criteria.
Statistical analysis
Statistical analyses were performed using Fisher’s exact test,
Mann–Whitney U-test or the log rank test when appropriate.
Time to treatment failure (TTF) was measured from the date of
inclusion to the time of progression or death or last follow-up,
whichever came ﬁrst, and assessed according to the Kaplan–Meier
method. Statistical analysis was performed using SPSS 9.0 software
(SPSS, Inc, Chicago, IL, USA).
Dose intensity (DI) was the total dose administered per square
metre divided by the number of weeks of treatment (Hryniuk
and Bush, 1984). For EPI, treatment duration was deﬁned as the
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Day 1
EC
Day 15
EC
Day 35
CPA/TTP
+ 28/35 days
CPA/TTP
+ 28/35 days
CPA/TTP
+ 28/35 days
CPA/TTP
:G-CSF injection :PBPC reinjection :Leukaphereses
Figure 1 Treatment plan: Leukaphereses were performed after the ﬁrst two courses of Epirubicin/Cyclophosphamide (EC). The four intensiﬁcation
courses with Cyclophosphamide and Thiotepa (CPA/TTP) were given every 28 to 35 days with PBPC and G-CSF support.
Table 1 Planned dose levels of cyclophosphamide and thiotepa. Each
drug was given four times, once every 4 to 5 weeks (mg m
72)
Level Cyclophosphamide Thiotepa
0 1500 200
1 2000 200
2 2000 250
3 2000 300
4 2000 400
5 3000 400
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chemotherapy cycle. For TTP, treatment duration was from the
ﬁrst day of the ﬁrst CPA/TTP to 28 days after the last chemother-
apy cycle actually received. For CPA, treatment duration was from
the ﬁrst EC to 28 days after the last chemotherapy cycle actually
received. DI calculations for each treatment course only take into
account the patients still receiving chemotherapy at that time.
RESULTS
Patient characteristics
Twenty-eight patients were enrolled into the study from January 6,
1995 to November 2, 1999 (Table 2). Median age was 42 years,
with seven patients under 35 years. Most patients had visceral loca-
lisation and 24 had measurable lesions. The median disease-free
interval was 1 year. Five patients were diagnosed with metastatic
disease at presentation. Ten patients were receptor-negative for
both oestrogen and progesterone. Of the 18 others, 14 had progres-
sive disease after one, two or three lines of hormonal therapy, and
four had rapidly progressive involvement of the liver requiring
chemotherapy. Finally, 19 patients (68%) had initially received
anthracycline-based adjuvant therapy.
Intermediate dose induction therapy and leukapheresis
Twenty-seven patients received the two planned EC cycles (Figure
2). One developed a staphylococcus infection on a hip implant after
the ﬁrst EC cycle and was withdrawn from the study. The EC regi-
men with G-CSF support was generally well tolerated, with no
grade 3 non-haematological toxicity except from vomiting (three
patients) and stomatitis (two patients). Haematological toxicity
was substantial: 24 (86%) and 22 (81%) patients had to be read-
mitted for febrile neutropenia after the ﬁrst and second EC
cycles, respectively. Nevertheless, 25 (89%) patients received their
second EC cycle on time (day 14 or 15) and at full doses. One
patient needed a dose reduction and one was postponed for 12
days for persistent thrombopenia. Twenty-six patients required
red blood cell transfusion and 15 required platelet transfusion.
Leukaphereses were performed after the ﬁrst and second EC. The
median number of leukaphereses per patients was ﬁve (range 2–
8). The median total CD34+ cells collected per patient was
18610
6 kg
71 (range 1.4–66.9).
Intensiﬁcation chemotherapy
Of the 27 patients who completed the induction treatment, two
were withdrawn because of insufﬁcient PBPC yield after six leuka-
phereses and one because of excessive haematological toxicity after
the EC cycles with a persistent grade 3 thrombopenia at day 50
(Figure 2).
Twenty-four patients received at least one CPA/TTP cycle and a
total of 87 courses were administered to this population. Eighteen
patients (64% of the accrued population) received the four planned
cycles. The dose of CPA and TTP were escalated through six dose
levels from 1500 to 3000 mg m
72 of CPA and 200 to 400 mg m
72
of TTP (Table 1). One patient discontinued treatment after two
cycles due to disease progression, two patients were withdrawn
from the study for persistent thrombopenia after the third cycle,
one patient died of toxicity after the ﬁrst cycle, one was withdrawn
after the third cycle for toxicity, and one refused therapy after the
third cycle (Figure 2). Treatment timing was respected for most
patients. The ﬁrst CPA/TTP was administered before day 36 for
all but nine patients for whom it was postponed for a median of
2 days (range 1–12 days). The second, third and fourth CPA/
TTP cycles were given on time to all patients but one who received
his fourth cycle on day 41 (median time from the previous cycle: 28
days; range 27–41 days). All patients were evaluable for toxicity.
Dose intensity
The median time from the ﬁrst EC cycle to the end of therapy
(deﬁned as four weeks after the last chemotherapy cycle actually
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First EC : n = 28
Second EC : n = 27
First CPA/TTP: n = 24
Second CPA/TTP: n = 23
Third CPA/TTP: n = 22
Fourtht CPA/TTP: n = 18
Three toxicity
One patient refusal
One progression
One toxic death (infection)
One toxicity
Two insufficient PBPC yield
One toxicity
Figure 2 Flow chart of the treatment course for the 28 patients.
Table 2 Patient characteristics (n=28)
Characteristics No. of patients
Age, median (range) 42 (24–60)
PS
01 5
11 1
22
Receptor status
ER or PR positive 14
ER and PRnNegative 10
Unknown 4
Adjuvant chemotherapy
Received 19
Not received 9
Prior hormonal therapy
Received 14
Not received 14
Disease-free interval
524 months 17
424 months 7
Metastatic site
Liver 15
Lung 11
Bone marrow 8
Number of metastatic sites
One 7
Two 11
Three or more 6
ER: estrogen receptor; PR: progesterone receptor.
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was 22 weeks for the 18 patients who completed the study (range
21–24 weeks). Median total doses and dose intensity for the whole
population are given in Table 3.
Haematological toxicity
Haematological toxicity was manageable on an outpatient basis. All
cycles were followed by grade 4 neutropenia and most patients had
to be readmitted for febrile neutropenia (deﬁned by grade 2/3 fever
and grade 4 neutropenia). Nevertheless, grade 4 neutropenia was of
short duration, with a median of 4 days (range 1–8 days); patients
were generally hospitalised for short periods, and hospitalisation
length did not increase signiﬁcantly with the number of cycles
for one given patient, nor with dose escalation for the population
as a whole (Table 4).
Similarly, grade 4 thrombocytopenia occurred in 78 of the 87
cycles (90%), regardless of the dose level or the number of courses
received. Platelet transfusion was given after 75 cycles (86%). The
median number of platelet units transfused per patients at each
cycle was 1 (range 0–4). Grade 3/4 anaemia requiring transfusion
occurred after 78 cycles (90%). All patients received red cell trans-
fusion with a median of 2 units per patients and per cycle (range
0–6). Finally, only two patients, at level 1, presented a haematolo-
gical DLT, i.e. a persistent grade 4 thrombopenia at day 35 of a
CPA/TTP cycle. Surprisingly, no other patient presented haemato-
logical DLT after dose escalation to levels 2 to 5.
Non-haematological toxicity
Grade 3 and 4 non-haematological toxicities at each dose level are
presented in Table 5. Most non-haematological toxicities were
expected and manageable. Alopecia (grade 2) was universal; one
patient (level 4) experienced persistent grade 1 alopecia 2 years
after completing treatment though she had received no other
chemotherapy. Grade 2 vomiting occurred in 12 out of 24 patients,
while grade 3 vomiting occurred in three; grade 2 nausea was
observed in seven patients; grade 2 and 3 diarrhoea was reported
in three and one patient, respectively. Constipation was rare (grade
2 in four patients) but haemorrhoids were frequent and sometimes
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Table 3 Total doses and dose intensity of EPI, CPA and TTP administered at the different dose levels. For DI calculation, only patients who actually
received the drug are taken into account
Median total doses Median DI
No. of
(mg m
72) (mg m
72 week
71)
Dose level patients EPI CPA TTP EPI CPA TTP
0 4 240 9985 801 47 473 50
1 8 239 11006 799 47 561 48
2 4 237 12128 1002 42 543 60
3 3 238 12129 1205 40 531 73
4 5 240 11987 1602 50 553 94
5 4 238 14491 1609 42 727 97
Total 28 239 12000 1001 45 542 61
Table 4 Febrile neutropenia and consecutive hospitalisation length (given in days) as a function of dose level and cycle number
Dose
Cycle 1 Cycle 2 Cycle 3 Cycle 4 Total
level n fn H. length n fn H. length n fn H. length n fn H. length n fn H. length
0 4 4 6 (5–8) 4 3 7 (5–8) 3 3 6 (5–6) 3 2 4 (4–4) 14 12 6 (4–8)
1 6 6 6 (5–8) 6 6 5 (3–8) 6 6 8 (3–17) 4 3 5 (4–6) 22 21 6 (3–17)
2 3 3 5 (5–6) 3 3 5 (3–7) 3 3 6 (4–7) 3 3 5 (3–6) 12 12 5 (3–7)
3 3 3 7 (4–10) 3 3 6 (5–7) 3 2 7 (5–9) 3 3 6 (5–8) 12 11 6 (4–10)
4 5 3 11 (4–24) 4 3 5 (4–5) 4 3 6 (3–10) 3 3 3 (1–5) 16 12 6 (1–24)
5 3 2 4 (3–5) 3 3 5 (3–7) 3 3 9 (5–16) 2 2 9 (5–13) 11 10 7 (3–16)
Total 24 21 7 (3–24) 23 20 5 (3–8) 22 20 7 (3–17) 18 16 5 (2–13) 87 78 6 (1–24)
n=number of treatment courses; fn=febrile neutropenia; H. length=medium hospitalisation length in days (range).
Table 5 Non-haematological grade 3–4 toxicities per patient at the different dose levels
Dose No. of Diarrhoea/ Infection
level patients Vomiting haemorrhoids Asthenia Grade 3 Grade 4 Total
04 0 0 04 0 4
16 1 0 03 0 4
23 1 0 01 0 2
33 0 0 11 1 3
45 1 2 11 1 6
53 0 0 10 2 3
Total 24 3 2 3 10 4 22
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tively). Most patients experienced mild stomatitis (grade 2 in 15
patients). Asthenia was signiﬁcant with eighteen patients (75%)
reporting grade 2 and two patients (8%) reporting grade 3 asthe-
nia. One patient at level 5 refused the fourth CPA/TTP as a
consequence of grade 3 asthenia, diarrhoea and vomiting. One
patient experienced a transient increase in creatinine level (grade
2); no cardiac or neurological toxicity was reported. The major
non-haematological toxicity was infection, with a total of 10
patients (42%) experiencing at least one episode of grade 3 infec-
tion with documented bacteriology. Four patients (17%)
experienced grade 4 infection: One patient suffered from a septic
shock following a staphylococcus septicaemia while in neutropenia
after the second CPA/TTP at level 3. This episode lasted only 4
days and resolved without any sequel; One patient at level 4 died
after the ﬁrst CPA/TTP cycle from overwhelming sepsis caused
by an antibiotic-resistant enterococcus while on intensive care for
pneumocystis pneumonia; Two patients at level 5 developed a
life-threatening lung infection after the third and fourth courses
of CPA/TTP, respectively (one caused by aspergillus and one caused
by pneumocystis carinii). As a consequence, we considered the
MTD to be reached and the study was stopped at level 5.
Initial lymphopenia and toxicity
Lymphopenia prior to the initiation of treatment is an independent
predictive factor for chemotherapy-induced toxicity (Blay et al,
1998; Ray-Coquard et al, 1999). In this population, the median
lymphocyte count before treatment was 1.25 G l
71 for the 18
patients who completed the treatment plan and only 0.8 for the
10 patients who did not (Mann–Whitney U-test, P=0.021).
Among the six patients whose day 1 lymphocyte count was below
0.7610
9 l
71, only two completed the treatment. One died after the
ﬁrst CPA/TTP (toxicity); one was progressive after the second
CPA/TTP; and two were withdrawn because of insufﬁcient PBPC
yield after six leukaphereses.
Response and survival
At the time of the ﬁrst CPA/TTP, 13 patients (46%) were consid-
ered by the investigator to be in partial response and 1 (4%) in
complete response. Seven patients had stable disease, four were
not evaluable for response but were not progressive, and three were
not evaluated. Two months after completion of the study, six
patients with stable disease after induction therapy were in partial
response, one patient in partial response after induction therapy
was in complete response, and three patients in partial response
after induction therapy were progressive. At that time, the inten-
tion-to-treat overall response rate was 17 out of 28 (60%). Of
the 24 evaluable patients, two had complete responses, 15 had
partial responses, two had stable diseases and ﬁve had progressive
diseases. Of the four patients with no measurable disease, two had
progressive disease, one was not evaluable for response but was not
progressive, and one was not evaluated (toxic death). The response
rate appeared to be slightly higher in patients treated at dose levels
3–5, with an overall response rate of 75%, as compared to 50% for
the 16 patients treated at dose levels 0–2 (Fisher’s exact test,
P=0.25).
At the time of analysis, the median follow up was 26 months.
The median TTF for the 28 patients was 11 months (95% conﬁ-
dence interval [CI]: 7–15; range 2–61+, Figure 3). The median
TTF of the 18 patients who completed the 4 cycles of CPA/TTP
was 12 months (95% CI: 10–14; range 5–61+). The median over-
all survival was 26 months (95% CI: 15–37; range 2–61+, Figure
3). One patient had died of toxicity, 23 patients had died of disease
progression, two were alive with progressive disease and three were
alive with no evidence of progressive disease 31, 55 and 61 months
after the ﬁrst EC cycle. Of those three long survivors, one was in
complete response, one in partial response and one in stable
disease after the ﬁrst 2 EC courses. Two were in complete response
and one in partial response after completion of the study.
Finally, the median survival of the six patients whose lympho-
cyte count at day 1 was below 0.7610
9 l
71 was only 8 months,
as compared to 34 months for the 18 other patients (log rank test,
P50.001).
DISCUSSION
Only few phase I studies have explored the maximum tolerated
dose of multiple sequential courses of HDCT in breast carcinoma,
as well as in other tumours. This study was designed to determine
the MTD of four courses of the association of high-dose CPA and
TTP given over 4 months with PBPC and G-CSF supports. Induc-
tion therapy consisted of two rapidly cycled courses of CPA (2 g
m
72) and EPI (120 mg m
72) with G-CSF supports followed by
haematopoietic stem cell collection through leukaphereses. At the
maximum tolerated dose, this protocol delivered 727 mg m
72
week
71 of CPA and 97 mg m
72 week
71 of TTP over a 5 month
period, which represents a 4–6-fold increase of the doses of
CPA as compared to conventional chemotherapy (Clavel and Cati-
mel, 1993; O’Dwyer et al, 1991). In addition, this mode of delivery
of CPA and TTP over four cycles enables to deliver twice as much
total dose as a single course of HDCT with bone marrow support
(Kennedy et al, 1991).
The association of G-CSF and PBPC supports allows rapid
haematological recovery after each cycle, making haematological
toxicities easily manageable on an outpatient basis (Basser et al,
1995; Rodenhuis et al, 1996; Viens et al, 1999). Interestingly,
haematological toxicity as evaluated by the duration of neutrope-
nia, thrombopenia, incidence of transfusion and delay to
haematopoietic reconstitution did not signiﬁcantly increase
between courses one and four for all patients in this study. Simi-
larly, no differences were observed between dose levels. Indeed,
the DLT of this program of four sequential HDCT courses was
not related to myeloid haematopoietic reconstitution.
In contrast, the rate of opportunistic infections, due to
chemotherapy-induced cumulative immunosuppression was found
to be the DLT of this study. Indeed, three opportunistic infections
(two pneumocistis pneumonia, one invasive lung aspergillus infec-
tion), were observed in the highest two dose levels tested (eight
patients). While these opportunistic infections are frequent after
allogenous bone marrow transplantation, they are infrequently
encountered after autologous bone marrow transplantation for
solid tumours, in particular using PBPC (Hartmann et al, 1997).
High-dose alkylating agents are known to impair T-cell immunity,
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of multiple HDCT courses results in a prolonged period of
profound lymphopenia, exposing the patient to a risk of opportu-
nistic infection (Mackall et al, 1994; Greenberg and Riddell, 1999).
Nevertheless, this treatment was associated with little life-threaten-
ing toxicity and only one treatment-related death.
Extra-haematological toxicities reported in this study of multiple
cycles of high-dose chemotherapy courses were found to be differ-
ent from the toxicity proﬁle of single very high-dose treatments
using the same drugs (Kennedy et al, 1991; Eder et al, 1990; Wolff
et al, 1990; Vahdat et al, 1995). Severe mucositis and neurological
toxicities where reported in single high dose treatment while in this
study mucositis was frequent but manageable (grade 2 in 62% of
the patients) and central nervous system toxicity was not observed
in any patient. This is likely to be related to the speciﬁc toxicity of
very high single doses of TTP (4700 mg m
72) that were not
reached in this study. Alternatively, as no pharmacokinetics analy-
sis has been made, we cannot rule out a metabolic interaction
between CPA and TTP. It has been described that continuous infu-
sion of TTP may inhibit the activation route of CPA (Huitema et
al, 2000). This could account for the absence of typical high-dose
CPA toxicities, such as haemorrhagic cystitis. Of note, treatment-
related fatigue was observed in a signiﬁcant proportion (83%) of
patients. This side effect is also less frequently reported in studies
of single HDCT.
Despite young age (median 42 years) and lack of prior therapy
for metastatic disease, only 18 out of 28 patients (64%) were able
to complete the whole treatment plan, whereas 10 were withdrawn
during treatment, two of them due to insufﬁcient PBPC collection
and seven due to excessive toxicity. Several other groups have
tested the association CPA/TTP in multiple-dose intensive
chemotherapy with different protocols. Vahdat et al (1995) admi-
nistered 2 courses of CPA (3 g m
72 course
71) and 2 courses of
TTP (500–700 mg m
72 course
71) to 42 patients over a 2-month
period. Most patients completed the study (90%), neurological
toxicity prevented further escalation of TTP. Two published studies
tested the CTC association (TTP, CPA, carboplatin,) on multiple
courses with PBPC support. In the report from Shapiro et al
(1997), four courses of caboplatin (200 mg m
72), CPA
1500 mg m
72 and TTP 125 mg m
72 were given every 21 to 42
days. Toxicity was moderate, with no toxic death, but, as in our
series, only 67% of the patients could complete the treatment
due to toxicity or disease progression. Rodenhuis et al (1996)
reported the results of a much more aggressive protocol which
consisted of carboplatin (1600 mg m
72), CPA (6000 mg m
72)
and TTP (480 mg m
72) for three courses every 28 days. Toxicity
was not acceptable after the second course. In a subsequent trial
with a 33% dose reduction, eight breast cancer patients were trea-
ted with ‘reasonable’ toxicity. Those results in terms of doses and
toxicities are consistent with our report. Taken together, they show
that despite manageable haematological toxicity in an outpatient
setting, multiple-dose intensive regimens would hardly be tolerated
by most patients in general practice, particularly in the case of
older patients (Antman, 2001).
The overall response rate (60%), median time to treatment fail-
ure (10 months) and median survival (26 months) achieved with
this regimen is comparable to that of previous studies of high-dose
therapy for metastatic disease. However, in these previous studies,
patients were randomised only if they responded to conventional
chemotherapy (Stadtmauer et al, 2000; Antman, 2001). In this
series, three patients were alive, free of progressive disease 31, 55
and 61 months after treatment, respectively. All had cytologically
conﬁrmed metastasis. This treatment approach may therefore be
curative in a small subset of patients.
In view of toxicity and long term survival rates, patient selection
will be of major importance in future studies, both to prevent
unacceptable toxicities and to discriminate the few patients who
are most likely to have a long-lasting response to this therapy. It
had been previously reported that the lymphocyte count was an
independent prognostic parameter of the toxicity of chemotherapy,
as well as a predictor of survival (Blay et al, 1998; Ray-Coquard et
al, 1999; Ray-Coquard et al, 2001). The present results support
these observations and further suggest that lymphocyte count could
be a useful parameter to evaluate the feasibility and toxic risks of
multiple courses of high-dose chemotherapy programs in clinical
practice. Nevertheless, this series was too small to perform a
complete statistical analysis that would take into account other
classical parameters. Further studies are required to assess the
importance of lymphopenia as a predictive factor for toxicity in
this setting.
In conclusion, we have shown that a regimen associating four
consecutive chemotherapy courses of high-dose CPA and TTP with
G-CSF and PBPC supports allows the administration on a 4-month
period of high dose-intensity and very high cumulative drug doses.
Toxicity was important, with one toxic death and only 18 of 24
patients completing the study, but manageable on an outpatient
basis. Response and survival are promising but few patients may
actually have a substantial survival beneﬁt from this treatment.
Better patient selection procedures are essential before new rando-
mised trials are initiated.
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